Core Insights - Memo Therapeutics AG has entered into a strategic collaboration and exclusive licensing option agreement with CSL for the MTx recombinant polyclonal IgG technology [1][4] - The total value of the agreement can reach up to 265 million Swiss Francs (approximately 328 million USD) [2][5] Group 1: Collaboration Details - MTx will utilize its proprietary DROPZYLLA® technology platform to develop recombinant polyclonal IgG products, which is designed for cloning human antibody libraries and expressing polyclonal antibodies [2][5] - CSL will receive exclusive licensing rights to MTx's technology, which allows for the large-scale capture and replication of natural human antibody libraries, enabling stable and controllable expression of diverse antibody populations [2][5] Group 2: Statements from Executives - MTx's CEO Erik van den Berg emphasized that IgG immunotherapy is used for treating various diseases, including congenital or acquired immunodeficiencies and autoimmune diseases, and that the collaboration validates their DROPZYLLA® technology platform [3][7] - CSL's Senior Vice President of Global Research, Dr. Michael Wilson, noted that the collaboration combines CSL's global leadership in immunoglobulin and recombinant protein expertise with Memo Therapeutics' technology to explore new treatment options for patients with rare and severe diseases [3][7]